Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

TAPUR: test dell'uso di farmaci approvati dalla Food and Drug Administration (FDA) che mirano a un'anomalia specifica in un gene tumorale nelle persone con cancro in stadio avanzato (TAPUR)

18 settembre 2026 aggiornato da: American Society of Clinical Oncology

Studio TAPUR (Targeted Agent and Profiling Utilization Registry).

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).

********************************************************************

Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.

********************************************************************

Panoramica dello studio

Descrizione dettagliata

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

Tipo di studio

Interventistico

Iscrizione (Stimato)

4200

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Laurie Smith, MA
  • Numero di telefono: www.tapur.org
  • Email: tapur@asco.org

Luoghi di studio

    • Puerto Rico
      • Cayey, Puerto Rico, Porto Rico, 00737
        • Reclutamento
        • PanOncology Trials
        • Contatto:
        • Investigatore principale:
          • Maria Cruz Correa, MD
      • Dorado, Puerto Rico, Porto Rico, 00646
        • Reclutamento
        • PanOncology Trials
        • Contatto:
        • Investigatore principale:
          • Maria Cruz Correa, MD
      • Manati, Puerto Rico, Porto Rico, 00674
        • Reclutamento
        • PanOncology Trials
        • Contatto:
        • Investigatore principale:
          • Maria Crus Correa, MD
      • Mayagüez, Puerto Rico, Porto Rico, 00680
        • Reclutamento
        • PanOncology Trials
        • Contatto:
        • Investigatore principale:
          • Maria Cruz Correa, MD
      • Ponce, Puerto Rico, Porto Rico, 00730
        • Reclutamento
        • PanOncology Trials
        • Contatto:
        • Investigatore principale:
          • Maria Cruz Correa, MD
      • San Juan, Puerto Rico, Porto Rico, 00909
        • Reclutamento
        • PanOncology Trials
        • Contatto:
        • Investigatore principale:
          • Maria Cruz Correa, MD
      • San Juan, Puerto Rico, Porto Rico, 00935
        • Reclutamento
        • PanOncology Trials
        • Contatto:
        • Investigatore principale:
          • Maria Cruz Correa, MD
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35294
        • Reclutamento
        • University of Alabama at Birmingham Comprehensive Cancer Center
        • Investigatore principale:
          • Mehmet Akce, MD
        • Contatto:
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85338
        • Reclutamento
        • Cancer Treatment Centers of America-Phoenix
        • Investigatore principale:
          • Sagun Shrestha, MD
        • Contatto:
    • California
      • Auburn, California, Stati Uniti, 95602
        • Reclutamento
        • Sutter Auburn
        • Contatto:
        • Investigatore principale:
          • Nitin Rohatgi, MD
      • Berkeley, California, Stati Uniti, 94705
        • Reclutamento
        • Sutter Alta Bates
        • Contatto:
        • Investigatore principale:
          • Nitin Rohatgi, MD
      • Los Angeles, California, Stati Uniti, 90025
        • Reclutamento
        • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
        • Contatto:
        • Investigatore principale:
          • Omid Hamid, MD
      • Oakland, California, Stati Uniti, 94611
        • Reclutamento
        • Kaiser Permanente - Oakland Medical Center
        • Contatto:
        • Investigatore principale:
          • Jennifer M Suga, MD
      • Palo Alto, California, Stati Uniti, 94301
      • Roseville, California, Stati Uniti, 95661
        • Reclutamento
        • Kaiser Permanente - Roseville Medical Center
        • Contatto:
        • Investigatore principale:
          • Jennifer M Suga, MD
      • Roseville, California, Stati Uniti, 95661
        • Reclutamento
        • Sutter Roseville
        • Contatto:
        • Investigatore principale:
          • Nitin Rohatgi, MD
      • Sacramento, California, Stati Uniti, 95814
        • Reclutamento
        • Kaiser Permanente - Sacramento Medical Center
        • Contatto:
        • Investigatore principale:
          • Jennifer M Suga, MD
      • Sacramento, California, Stati Uniti, 95816
        • Reclutamento
        • Sutter Sacramento
        • Contatto:
        • Investigatore principale:
          • Nitin Rohatgi, MD
      • San Francisco, California, Stati Uniti, 94115
        • Reclutamento
        • California Pacific Medical Center Research Institute
        • Contatto:
        • Investigatore principale:
          • Nitin Rohatgi, MD
      • San Francisco, California, Stati Uniti, 94080
        • Reclutamento
        • Kaiser Permanente - South San Francisco Medical Center
        • Contatto:
        • Investigatore principale:
          • Jennifer M Suga, MD
      • San Francisco, California, Stati Uniti, 94115
        • Reclutamento
        • Kaiser Permanente - San Francisco Medical Center
        • Contatto:
        • Investigatore principale:
          • Jennifer M Suga, MD
      • San Francisco, California, Stati Uniti, 94115
        • Reclutamento
        • Sutter Cancer Research Consortium
        • Contatto:
        • Investigatore principale:
          • Stacy D'Andre, MD
      • San Jose, California, Stati Uniti, 95119
        • Reclutamento
        • Kaiser Permanente - San Jose Medical Center
        • Contatto:
        • Investigatore principale:
          • Jennifer M Suga, MD
      • San Leandro, California, Stati Uniti, 94577
        • Reclutamento
        • Kaiser Permanente - San Leandro Medical Center
        • Contatto:
        • Investigatore principale:
          • Jennifer M Suga, MD
      • Santa Barbara, California, Stati Uniti, 93105
        • Reclutamento
        • Sutter Sansum Clinic
        • Investigatore principale:
          • Nitin Rohatgi, MD
        • Contatto:
      • Santa Clara, California, Stati Uniti, 95051
        • Reclutamento
        • Kaiser Permanente - Santa Clara Medical Center
        • Contatto:
        • Investigatore principale:
          • Jennifer M Suga, MD
      • Santa Cruz, California, Stati Uniti, 95065
      • Santa Cruz, California, Stati Uniti, 994538
      • Sunnyvale, California, Stati Uniti, 94086
      • Vallejo, California, Stati Uniti, 94589
        • Reclutamento
        • Kaiser Permanente - Vallejo Medical Center
        • Contatto:
        • Investigatore principale:
          • Jennifer M. Suga, MD
      • Walnut Creek, California, Stati Uniti, 94596
        • Reclutamento
        • Kaiser Permanente - Walnut Creek Medical Center
        • Contatto:
        • Investigatore principale:
          • Jennifer M Suga, MD
    • Connecticut
      • Bridgeport, Connecticut, Stati Uniti, 06606
        • Reclutamento
        • Saint Vincent's Medical Center (SVMC)
        • Contatto:
        • Investigatore principale:
          • Wylie Hosmer, MD
      • Hartford, Connecticut, Stati Uniti, 06102
      • Meriden, Connecticut, Stati Uniti, 06451
      • New Britain, Connecticut, Stati Uniti, 06053
        • Reclutamento
        • The Hospital of Central Connecticut (HOCC) Cancer Center
        • Investigatore principale:
          • Wylie Hosmer, MD
        • Contatto:
      • Norwich, Connecticut, Stati Uniti, 06360
      • Torrington, Connecticut, Stati Uniti, 06790
      • Willimantic, Connecticut, Stati Uniti, 06226
    • Florida
      • Altamonte Springs, Florida, Stati Uniti, 32701
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Aventura, Florida, Stati Uniti, 33180
        • Reclutamento
        • University of Miami/Sylvester Cancer Institute - Aventura
        • Contatto:
        • Investigatore principale:
          • Carmen Calfa, MD
      • Bonita Springs, Florida, Stati Uniti, 34135
        • Attivo, non reclutante
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Bradenton, Florida, Stati Uniti, 34211
        • Attivo, non reclutante
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Brandon, Florida, Stati Uniti, 33511
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Cape Coral, Florida, Stati Uniti, 33909
        • Attivo, non reclutante
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Clearwater, Florida, Stati Uniti, 33761
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Coral Gables, Florida, Stati Uniti, 33146
        • Reclutamento
        • University of Miami/Sylvester Cancer Institute - Lennar
        • Contatto:
        • Investigatore principale:
          • Carmen Calfa, MD
      • Deerfield Beach, Florida, Stati Uniti, 33442
        • Reclutamento
        • University of Miami/Sylvester Cancer Institute - Deerfield Beach
        • Contatto:
        • Investigatore principale:
          • Carmen Calfa, MD
      • Fort Lauderdale, Florida, Stati Uniti, 33308
      • Fort Myers, Florida, Stati Uniti, 33901
        • Attivo, non reclutante
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Fort Myers, Florida, Stati Uniti, 33905
        • Attivo, non reclutante
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Fort Myers, Florida, Stati Uniti, 33908
        • Attivo, non reclutante
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Gainesville, Florida, Stati Uniti, 32610
        • Reclutamento
        • University of Florida Health
        • Investigatore principale:
          • Thomas George, MD
        • Contatto:
          • Anna Kukulka, RN, BSN
          • Numero di telefono: 352-293-2551
          • Email: akukulka@ufl.edu
      • Gainesville, Florida, Stati Uniti, 32605
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Largo, Florida, Stati Uniti, 33770
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Lecanto, Florida, Stati Uniti, 34461
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Miami, Florida, Stati Uniti, 33136
        • Reclutamento
        • University of Miami Sylvester Comprehensive Cancer Center
        • Contatto:
        • Investigatore principale:
          • Carmen Calfa, MD
      • Miami, Florida, Stati Uniti, 33136
        • Reclutamento
        • University of Miami/Sylvester Cancer Institute - Alex's Place
        • Contatto:
        • Investigatore principale:
          • Carmen Calfa, MD
      • Miami, Florida, Stati Uniti, 33136
        • Reclutamento
        • University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building
        • Contatto:
        • Investigatore principale:
          • Carmen Calfa, MD
      • Miami, Florida, Stati Uniti, 33176
        • Reclutamento
        • University of Miami/Sylvester Cancer Institute - Kendall
        • Contatto:
        • Investigatore principale:
          • Carmen Calfa, MD
      • Miami, Florida, Stati Uniti, 33181
        • Reclutamento
        • University of Miami/Sylvester Cancer Institute - Sole Mia
        • Contatto:
        • Investigatore principale:
          • Carmen Calfa, MD
      • Naples, Florida, Stati Uniti, 34102
        • Attivo, non reclutante
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Ocala, Florida, Stati Uniti, 34474
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Orange City, Florida, Stati Uniti, 32763
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Orlando, Florida, Stati Uniti, 32806
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Plantation, Florida, Stati Uniti, 33324
        • Reclutamento
        • University of Miami/Sylvester Cancer Institute - Plantation
        • Contatto:
        • Investigatore principale:
          • Carmen Calfa, MD
      • Port Charlotte, Florida, Stati Uniti, 33980
        • Attivo, non reclutante
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Sarasota, Florida, Stati Uniti, 34236
        • Attivo, non reclutante
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Sarasota, Florida, Stati Uniti, 34239
        • Attivo, non reclutante
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • St. Petersburg, Florida, Stati Uniti, 33701
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Tampa, Florida, Stati Uniti, 33607
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Tavares, Florida, Stati Uniti, 32778
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • The Villages, Florida, Stati Uniti, 32159
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Trinity, Florida, Stati Uniti, 34655
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Venice, Florida, Stati Uniti, 34285
        • Attivo, non reclutante
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Venice, Florida, Stati Uniti, 34292
        • Attivo, non reclutante
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Winter Park, Florida, Stati Uniti, 32789
        • Attivo, non reclutante
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Emory University Winship Cancer Institute
        • Investigatore principale:
          • Olatunji Alese, MD
        • Contatto:
      • Atlanta, Georgia, Stati Uniti, 30265
        • Reclutamento
        • Cancer Treatment Centers of America - Atlanta
        • Investigatore principale:
          • Bamidele Adesunloye, MD
        • Contatto:
          • Elizabeth McKoy, RN, BSN
          • Numero di telefono: 770-400-7177
          • Email: emckoy@coh.org
      • Savannah, Georgia, Stati Uniti, 31405
        • Reclutamento
        • Summit Cancer Care
        • Investigatore principale:
          • Mark Taylor, MD
        • Contatto:
          • Stephanie Smith, RN, MSN, OCN
          • Numero di telefono: 9128195723
          • Email: smiths1@sjchs.org
      • Savannah, Georgia, Stati Uniti, 31405
        • Reclutamento
        • Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
        • Investigatore principale:
          • Mark Taylor, MD
        • Contatto:
          • Stephanie Smith, RN, MSN, OCN
          • Numero di telefono: 9128195723
          • Email: smiths1@sjchs.org
      • Savannah, Georgia, Stati Uniti, 31405
        • Reclutamento
        • Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
        • Investigatore principale:
          • Mark Taylor, MD
        • Contatto:
          • Stephanie Smith, RN, MSN, OCN
          • Numero di telefono: 19128195723
          • Email: smiths1@sjchs.org
      • Savannah, Georgia, Stati Uniti, 31405
        • Reclutamento
        • Lewis Cancer & Research Pavilion
        • Contatto:
          • Stephanie Smith, RN, MSN, OCN
          • Numero di telefono: 912-819-5723
          • Email: smiths1@sjchs.org
        • Investigatore principale:
          • Mark Taylor, MD
    • Hawaii
      • Honolulu, Hawaii, Stati Uniti, 96813
        • Reclutamento
        • The Queen's Medical Center - POB I
        • Investigatore principale:
          • Jared Acoba, MD
        • Contatto:
      • Honolulu, Hawaii, Stati Uniti, 96813
        • Reclutamento
        • The Queen's Medical Center - Punchbowl
        • Investigatore principale:
          • Jared Acoba, MD
        • Contatto:
      • Honolulu, Hawaii, Stati Uniti, 96817
        • Reclutamento
        • The Queen's Medical Center - Kuakini
        • Investigatore principale:
          • Jared Acoba, MD
        • Contatto:
      • ‘Ewa Beach, Hawaii, Stati Uniti, 96706
        • Reclutamento
        • The Queen's Medical Center - West Oahu
        • Investigatore principale:
          • Jared Acoba, MD
        • Contatto:
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60099
        • Reclutamento
        • Cancer Treatment Centers of America-Chicago
        • Investigatore principale:
          • Evan Pisick, MD
        • Contatto:
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46250
        • Reclutamento
        • Community Health Network (The University of Texas MD Anderson Cancer Center)
        • Investigatore principale:
          • Funda Meric-Bernstam, MD
        • Contatto:
    • Maine
      • Augusta, Maine, Stati Uniti, 04330
        • Reclutamento
        • Harold Alfond Center for Cancer Care
        • Contatto:
        • Investigatore principale:
          • Lindsay Hathaway, MD
      • Augusta, Maine, Stati Uniti, 04330
        • Reclutamento
        • Jackson Laboratory - Maine Cancer Genomics Initiative
        • Contatto:
        • Investigatore principale:
          • Jens Rueter, MD
      • Belfast, Maine, Stati Uniti, 04915
        • Reclutamento
        • Waldo County General Hospital
        • Investigatore principale:
          • Roger Inhorn, MD
        • Contatto:
          • Jen - Dalton, MHA, BSN, RN
          • Numero di telefono: 2072948291
          • Email: JDalton@mmc.org
      • Biddeford, Maine, Stati Uniti, 04005
        • Reclutamento
        • SMHC Cancer Care and Blood Disorders -Biddeford
        • Investigatore principale:
          • Roger Inhorn, MD
        • Contatto:
      • Brewer, Maine, Stati Uniti, 04412
        • Reclutamento
        • Northern Light Cancer Care
        • Investigatore principale:
          • Sarah Sinclair, MD
        • Contatto:
      • Brewer, Maine, Stati Uniti, 04412
        • Reclutamento
        • Raish Peavey Haskell Children's Cancer and Treatment Center
        • Investigatore principale:
          • Sarah Sinclair, MD
        • Contatto:
      • Brunswick, Maine, Stati Uniti, 04011
        • Reclutamento
        • MaineHealth Cancer Care -Brunswick
        • Investigatore principale:
          • Roger Inhorn, MD
        • Contatto:
          • Jen - Dalton, MHA, BSN, RN
          • Numero di telefono: 2072948291
          • Email: JDalton@mmc.org
      • Kennebunk, Maine, Stati Uniti, 04043
        • Reclutamento
        • New England Cancer Specialist
        • Investigatore principale:
          • Christian Thomas, MD
        • Contatto:
      • Kittery, Maine, Stati Uniti, 03904
        • Reclutamento
        • York Hopsital Oncology & Infusion Care in Kittery
        • Investigatore principale:
          • Marilyn McLaughlin, MD
        • Contatto:
      • Norway, Maine, Stati Uniti, 04268
        • Reclutamento
        • Stephens Memorial Hospital
        • Investigatore principale:
          • Roger Inhorn, MD
        • Contatto:
          • Jen - Dalton, MHA, BSN, RN
          • Numero di telefono: 2072948291
          • Email: JDalton@mmc.org
      • Rockport, Maine, Stati Uniti, 04856
        • Reclutamento
        • Penobscot Bay Medical Center
        • Investigatore principale:
          • Roger Inhorn, MD
        • Contatto:
          • Jen - Dalton, MHA, BSN, RN
          • Numero di telefono: 2072948291
          • Email: JDalton@mmc.org
      • Sanford, Maine, Stati Uniti, 04073
        • Reclutamento
        • SMHC Cancer Care and Blood Disorders -Sandford
        • Investigatore principale:
          • Roger Inhorn, MD
        • Contatto:
          • Jen - Dalton, MHA, BSN, RN
          • Numero di telefono: 2072948291
          • Email: JDalton@mmc.org
      • Scarborough, Maine, Stati Uniti, 04074
        • Reclutamento
        • Maine Children's Cancer Program
        • Investigatore principale:
          • Roger Inhorn, MD
        • Contatto:
          • Jen - Dalton, MHA, BSN, RN
          • Numero di telefono: 2072948291
          • Email: JDalton@mmc.org
      • Scarborough, Maine, Stati Uniti, 04074
        • Reclutamento
        • Maine Medical Partner's Women's Health
        • Investigatore principale:
          • Roger Inhorn, MD
        • Contatto:
          • Jen - Dalton, MHA, BSN, RN
          • Numero di telefono: 2072948291
          • Email: JDalton@mmc.org
      • Scarborough, Maine, Stati Uniti, 04074
        • Reclutamento
        • New England Cancer Specialist
        • Investigatore principale:
          • Christian Thomas, MD
        • Contatto:
          • Patricia Collins, BA, CCRC
          • Numero di telefono: 207-303-3422
          • Email: collip@newecs.org
      • South Portland, Maine, Stati Uniti, 04106
        • Reclutamento
        • MaineHealth Cancer Care -South Portland
        • Contatto:
          • Jen Dalton, MHA, BSN, RN
          • Numero di telefono: 207-294-8291
          • Email: JDalton@mmc.org
        • Investigatore principale:
          • Roger Inhorn, MD
      • Topsham, Maine, Stati Uniti, 04086
        • Reclutamento
        • New England Cancer Specialist
        • Investigatore principale:
          • Christian Thomas, MD
        • Contatto:
          • Patricia C Collins, BA, CCRC
          • Numero di telefono: 12073033422
          • Email: collip@newecs.org
      • Wells, Maine, Stati Uniti, 04090
        • Reclutamento
        • York Hospital Oncology & Infusion Care in Wells
        • Investigatore principale:
          • Marilyn McLaughlin, MD
        • Contatto:
      • York Village, Maine, Stati Uniti, 03909
        • Reclutamento
        • York Hospital Oncology & Infusion Care in York
        • Investigatore principale:
          • Marilyn McLaughlin, MD
        • Contatto:
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Attivo, non reclutante
        • University of Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48106
      • Detroit, Michigan, Stati Uniti, 48236
      • Flint, Michigan, Stati Uniti, 48503
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Reclutamento
        • Cancer Research Consortium of West Michigan
        • Contatto:
        • Investigatore principale:
          • Kathleen J. Yost, MD
      • Lansing, Michigan, Stati Uniti, 48912
      • Livonia, Michigan, Stati Uniti, 48154
      • Pontiac, Michigan, Stati Uniti, 48341
      • Saginaw, Michigan, Stati Uniti, 48601
      • Traverse City, Michigan, Stati Uniti, 48341
        • Reclutamento
        • Michigan Cancer Research Consortium
        • Investigatore principale:
          • Philip Stella, MD
        • Contatto:
        • Contatto:
          • Numero di telefono: 877-590-5995
      • Warren, Michigan, Stati Uniti, 48093
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68198
        • Reclutamento
        • University of Nebraska Medical Center
        • Investigatore principale:
          • Alissa Marr, MD
        • Contatto:
    • New Hampshire
      • Concord, New Hampshire, Stati Uniti, 03103
        • Reclutamento
        • NH Oncology - Hematology, PA
        • Contatto:
        • Investigatore principale:
          • Michael Buff, MD
      • Manchester, New Hampshire, Stati Uniti, 03103
        • Reclutamento
        • Solinsky Center for Cancer Care
        • Contatto:
        • Investigatore principale:
          • Michael Buff, MD
      • Portsmouth, New Hampshire, Stati Uniti, 03801
        • Reclutamento
        • New England Cancer Specialist
        • Investigatore principale:
          • Christian Thomas, MD
        • Contatto:
          • Patricia C Collins, BA, CCRC
          • Numero di telefono: 2073033422
          • Email: collip@newecs.org
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87110
        • Reclutamento
        • Presbyterian Kaseman Hospital
        • Investigatore principale:
          • Bernard Tawfik, MD
        • Contatto:
      • Albuquerque, New Mexico, Stati Uniti, 87102
        • Reclutamento
        • Lovelace Medical Center - Saint Joseph Square
        • Investigatore principale:
          • Bernard Tawfik, MD
        • Contatto:
      • Albuquerque, New Mexico, Stati Uniti, 87131
        • Reclutamento
        • The University of New Mexico Comprehensive Cancer Center
        • Investigatore principale:
          • Bernard Tawfik, MD
        • Contatto:
      • Las Cruces, New Mexico, Stati Uniti, 88011
        • Reclutamento
        • Memorial Medical Center
        • Investigatore principale:
          • Bernard Tawfik, MD
        • Contatto:
      • Rio Rancho, New Mexico, Stati Uniti, 87124
        • Reclutamento
        • Presbyterian Rust Medical Center
        • Investigatore principale:
          • Bernard Tawfik, MD
        • Contatto:
          • Andrea Yost
          • Numero di telefono: (505) -253-7878
          • Email: ayost3@phs.org
    • New York
      • Lake Success, New York, Stati Uniti, 11042
        • Reclutamento
        • Northwell Health Monter Cancer Center
        • Contatto:
        • Investigatore principale:
          • Marina Frimer, MD
      • Mount Kisco, New York, Stati Uniti, 10549
        • Reclutamento
        • Northern Westchester Hospital
        • Investigatore principale:
          • Marina Frimer, MD
        • Contatto:
      • New Hyde Park, New York, Stati Uniti, 11040
        • Reclutamento
        • Cohen Children's Medical Center
        • Contatto:
        • Investigatore principale:
          • Marina Frimer, MD
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Manhattan Eye, Ear, and Throat Hospital
        • Investigatore principale:
          • Marina Frimer, MD
        • Contatto:
      • New York, New York, Stati Uniti, 10305
        • Reclutamento
        • Staten Island University Hospital
        • Investigatore principale:
          • Marina Frimer, MD
        • Contatto:
        • Contatto:
      • Rego Park, New York, Stati Uniti, 11374
        • Reclutamento
        • Queens Cancer Center
        • Investigatore principale:
          • Marina Frimer, MD
        • Contatto:
      • Sleepy Hollow, New York, Stati Uniti, 10591
        • Reclutamento
        • Phelps Hospital
        • Investigatore principale:
          • Marina Frimer, MD
        • Contatto:
        • Contatto:
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27599
        • Reclutamento
        • Lineberger Comprehensive Cancer Center
        • Investigatore principale:
          • Shetal Patel, MD
        • Contatto:
      • Charlotte, North Carolina, Stati Uniti, 28277
        • Reclutamento
        • Atrium Health's Levine Cancer Institute
        • Investigatore principale:
          • Kathryn F. Mileham, MD, FACP
        • Contatto:
    • North Dakota
      • Bismarck, North Dakota, Stati Uniti, 58501
        • Reclutamento
        • Sanford Health- Bismarck
        • Contatto:
        • Investigatore principale:
          • Peter Kurniali, MD
      • Fargo, North Dakota, Stati Uniti, 58122
        • Reclutamento
        • Sanford Health- Fargo
        • Contatto:
        • Investigatore principale:
          • Anu Gaba, MD
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45219
        • Reclutamento
        • University of Cincinnati Medical Center
        • Investigatore principale:
          • Davendra Sohal, MD
        • Contatto:
      • Kettering, Ohio, Stati Uniti, 45429
        • Reclutamento
        • Kettering Health
        • Contatto:
        • Investigatore principale:
          • Lex Leonhardt, DO
      • West Chester, Ohio, Stati Uniti, 45069
        • Reclutamento
        • West Chester Hospital
        • Investigatore principale:
          • Trisha Wise-Draper, MD
        • Contatto:
    • Oregon
      • Portland, Oregon, Stati Uniti, 97213
        • Reclutamento
        • Providence Health & Services
        • Investigatore principale:
          • Evthokia Hobbs, MD
        • Contatto:
    • Pennsylvania
      • Allentown, Pennsylvania, Stati Uniti, 18103
      • Bethlehem, Pennsylvania, Stati Uniti, 18017
      • East Stroudsburg, Pennsylvania, Stati Uniti, 18301
      • Hazleton, Pennsylvania, Stati Uniti, 18201
      • Philadelphia, Pennsylvania, Stati Uniti, 19111
        • Reclutamento
        • Fox Chase Cancer Center
        • Investigatore principale:
          • Margaret von Mehren, MD
        • Contatto:
    • South Carolina
      • Bluffton, South Carolina, Stati Uniti, 29910
        • Reclutamento
        • SC Cancer Specialists at St. Joseph's/Candler Bluffton
        • Investigatore principale:
          • Mark Taylor, MD
        • Contatto:
          • Stephanie Smith, RN, MSN, OCN
          • Numero di telefono: 19128195723
          • Email: smiths1@sjchs.org
      • Bluffton, South Carolina, Stati Uniti, 29910
        • Reclutamento
        • St. Joseph's/Candler Smith
        • Investigatore principale:
          • Mark Taylor, MD
        • Contatto:
          • Stephanie Smith, RN, MSN, OCN
          • Numero di telefono: 19128195723
          • Email: smiths1@sjchs.org
      • Bluffton, South Carolina, Stati Uniti, 29910
        • Reclutamento
        • Summit Cancer Care at St. Josph's/Candler Bluffton
        • Investigatore principale:
          • Mark Taylor, MD
        • Contatto:
          • Stephanie Smith, RN, MSN, OCN
          • Numero di telefono: 19128195723
          • Email: smiths1@sjchs.org
      • Hilton Head Island, South Carolina, Stati Uniti, 29926
        • Reclutamento
        • South Carolina Cancer Specialists
        • Investigatore principale:
          • Mark Taylor, MD
        • Contatto:
          • Stephanie Smith, RN, MSN, OCN
          • Numero di telefono: 19128195723
          • Email: smiths1@sjchs.org
    • South Dakota
      • Sioux Falls, South Dakota, Stati Uniti, 57104
        • Reclutamento
        • Sanford Cancer Center Oncology Clinic and Pharmacy
        • Investigatore principale:
          • Steven Powell, MD
        • Contatto:
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • Reclutamento
        • Tennessee Oncology - Nashville / Sarah Cannon Research Institute
        • Contatto:
        • Investigatore principale:
          • Meredith McKean, MD, MPH
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • The University of Texas MD Anderson Cancer Center
        • Investigatore principale:
          • Funda Meric-Bernstam, MD
        • Contatto:
    • Utah
      • Cedar City, Utah, Stati Uniti, 84720
        • Reclutamento
        • Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
        • Investigatore principale:
          • Ramya Thota, MD
        • Contatto:
        • Investigatore principale:
          • Derrick Haslem, MD
      • Salt Lake City, Utah, Stati Uniti, 84107
        • Reclutamento
        • Intermountain Healthcare
        • Contatto:
        • Investigatore principale:
          • Ramya Thota, M.D.
        • Investigatore principale:
          • Derrick Haslem, M.D.
      • St. George, Utah, Stati Uniti, 84770
        • Reclutamento
        • Dixie Regional Medical Center-River Road Campus
        • Investigatore principale:
          • Ramya Thota, MD
        • Contatto:
        • Investigatore principale:
          • Derrick Haslem, MD
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22042
        • Reclutamento
        • Inova Schar Cancer Institute
        • Investigatore principale:
          • Timothy Cannon, MD
        • Contatto:
    • Washington
      • Bonney Lake, Washington, Stati Uniti, 98391
        • Reclutamento
        • Northwest Medical Specialties
        • Contatto:
        • Investigatore principale:
          • Frank Senecal, MD
      • Federal Way, Washington, Stati Uniti, 98003
        • Reclutamento
        • Northwest Medical Specialties
        • Contatto:
        • Investigatore principale:
          • Frank Senecal, MD
      • Gig Harbor, Washington, Stati Uniti, 98332
        • Reclutamento
        • Northwest Medical Specialties
        • Contatto:
        • Investigatore principale:
          • Frank Senecal, MD
      • Olympia, Washington, Stati Uniti, 98502
        • Reclutamento
        • Northwest Medical Specialties
        • Contatto:
        • Investigatore principale:
          • Frank Senecal, MD
      • Puyallup, Washington, Stati Uniti, 98373
        • Reclutamento
        • Northwest Medical Specialties
        • Investigatore principale:
          • Frank Senecal, MD
        • Contatto:
      • Seattle, Washington, Stati Uniti, 98104
        • Reclutamento
        • Swedish Cancer Institute
        • Investigatore principale:
          • Philip Gold, MD
        • Contatto:
      • Tacoma, Washington, Stati Uniti, 98405
        • Reclutamento
        • Northwest Medical Specialties
        • Investigatore principale:
          • Frank Senecal, MD
        • Contatto:
    • Wisconsin
      • Burlington, Wisconsin, Stati Uniti, 53105
        • Reclutamento
        • Aurora Cancer Care - Burlington
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Germantown, Wisconsin, Stati Uniti, 53022
        • Reclutamento
        • Aurora Health Care - Germantown Health Center
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Grafton, Wisconsin, Stati Uniti, 53024
        • Reclutamento
        • Aurora Cancer Care - Grafton
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Green Bay, Wisconsin, Stati Uniti, 54311
        • Reclutamento
        • Aurora BayCare Medical Center
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Kenosha, Wisconsin, Stati Uniti, 53142
        • Reclutamento
        • Aurora Cancer Care - Kenosha South
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Marinette, Wisconsin, Stati Uniti, 54143
        • Reclutamento
        • Aurora Bay Area Medical Center
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Milwaukee, Wisconsin, Stati Uniti, 53215
        • Reclutamento
        • Aurora St. Luke's Medical Center
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Milwaukee, Wisconsin, Stati Uniti, 53209
        • Reclutamento
        • Aurora Cancer Care Milwaukee
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Milwaukee, Wisconsin, Stati Uniti, 53223
        • Reclutamento
        • Aurora Sinai Medical Center
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Milwaukee, Wisconsin, Stati Uniti, 53227
        • Reclutamento
        • Aurora West Allis Medical Center
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Oshkosh, Wisconsin, Stati Uniti, 54904
        • Reclutamento
        • Vince Lombardi Cancer Clinic - Oshkosh
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Racine, Wisconsin, Stati Uniti, 53406
        • Reclutamento
        • Aurora Cancer Care - Racine
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Sheboygan, Wisconsin, Stati Uniti, 53081
        • Reclutamento
        • Vince Lombardi Cancer Center
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Summit, Wisconsin, Stati Uniti, 53066
        • Reclutamento
        • Aurora Medical Center in Summit
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Two Rivers, Wisconsin, Stati Uniti, 54241
        • Reclutamento
        • Vince Lombardi Cancer Clinic - Two Rivers
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:
      • Wauwatosa, Wisconsin, Stati Uniti, 53226
        • Reclutamento
        • Aurora Cancer Care - Milwaukee West
        • Investigatore principale:
          • Antony Ruggeri, MD
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

12 anni e precedenti (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • 12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)

  • Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication).

  • Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)

  • Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:

    1. Absolute neutrophil count ≥ 1500 µl
    2. Hemoglobin ≥ 9.0 g/dl
    3. Platelets ≥ 75,000/µl
    4. Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
    5. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
    6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
  • Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma).

  • Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.

  • Ability to understand and the willingness to sign a written informed consent/assent document.

  • Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.

  • For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.

  • Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse.

Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.

Exclusion Criteria:

  • Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
  • Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded
  • Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
  • Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.

Note: there are additional exclusion criteria that may apply

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Altro: Group 5 (CSF1R,PDGFR,VEGFR)

Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations

drug

Altri nomi:
  • Sutent
Altro: Group 8 (ERBB2)

Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations

drug

Altri nomi:
  • Herceptin e Perjeta
Altro: Group 9 (BRAF V600E/D/K/R)

Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations

drug

Altri nomi:
  • Zelboraf e Cotellic
Altro: Group 14 (BRCA1/2; ATM)

Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions

drug

Altri nomi:
  • Lynparz
Altro: Group 16 (MSI-H, high mutational load and others)

Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations

drug

Altri nomi:
  • Opdivo e Yervoy
Altro: Group 17 (CDKN2A, CDK4, CDK6)

Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation

drug

Altri nomi:
  • Verzenio
Altro: Group 19 (BRCA1/2, PALB2)

Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations

drug

Altri nomi:
  • Talzenna
Altro: Group 21 (BRCA1/2, PALB2, ATM, and others)

Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval

drug

Altri nomi:
  • Tecentriq e Talzenna
Altro: Group 24 (ERBB2)

Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations

drug

Altri nomi:
  • Tukysa e Herceptin Hylecta
Altro: Group 25

Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation

drug

Altri nomi:
  • Lytgobi
Altro: Group 26 (BRAF V600 E mutation )

Participants receive Dabrafenib plus Trametinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600 E mutation .

Drug

Altri nomi:
  • Mekinista
  • tanfinlar
Altro: Group 27 (ERBB2 amplification, ERBB2 (HER2) IHC2+ or IHC3+ overexpression)

Participants receive Fam-trastuzumab deruxtecan-nxki (ENHERTU®) - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification, For NSCLC Only-ERBB2 (HER2) IHC2+ or IHC3+ overexpression without ERBB2 amplification)

Drug

Altri nomi:
  • Enhertu

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Lasso di tempo: Assessed at 16 weeks of treatment

Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.

Assessed at 16 weeks of treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall survival (OS)
Lasso di tempo: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years

OS will be estimated using the Kaplan-Meier method

Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

14 marzo 2016

Completamento primario (Stimato)

31 dicembre 2027

Completamento dello studio (Stimato)

31 dicembre 2028

Date di iscrizione allo studio

Primo inviato

11 febbraio 2016

Primo inviato che soddisfa i criteri di controllo qualità

23 febbraio 2016

Primo Inserito (Stimato)

26 febbraio 2016

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

18 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi